News Search Results
Mar 26, 2025, 07:16 ET Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
March 26, 2025 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical
More news about: OSR Holdings Inc.
Mar 26, 2025, 07:05 ET Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended
More news about: Leap Therapeutics, Inc.
Mar 26, 2025, 07:00 ET Rice Biotech Launch Pad and RBL LLC to celebrate official launch and lab opening
field of biotechnology as a whole," Rice President Reginald DesRoches said. "Langer has been an incredible leader in translational medicine, pioneering breakthroughs that have transformed drug delivery, tissue engineering and biotechnology and improved
More news about: Rice University
Mar 26, 2025, 07:00 ET Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
our confidence in our innovative approach to treat fibrotic diseases." About Tribune TherapeuticsTribune Therapeutics is a biotechnology company advancing novel medicines to treat fibrosis, regardless of the cause, tissue or diagnosis. The company was founded on groundbreaking structural
More news about: Novo Holdings
Mar 26, 2025, 07:00 ET Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study
More news about: Leap Therapeutics, Inc.
Mar 26, 2025, 06:29 ET ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024
Sichuan Kelun Pharmaceutical Co., Ltd., specializing in the R&D, production, commercialization, and international collaboration of innovative biotechnology and small-molecule drugs. The Company focuses on addressing unmet clinical needs both globally and in China, with
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Mar 26, 2025, 06:21 ET Innovent Announces 2024 Annual Results and Business Updates
practices Innovent has been graded 'AAA' rating in MSCI ESG rankings, positioning us at the forefront of the biotechnology industry.We recently launched our ESG website to further strengthen commitment to sustainability, corporate responsibility and ethical
More news about: Innovent Biologics
Mar 26, 2025, 06:00 ET DATAcc by DiMe Releases Resources to Build the Business Case for Digital Endpoints
helps you navigate their roles across different stages of development.The Digital Endpoints ROI Calculator supports pharmaceutical, biotechnology, and digital health technology stakeholders in making data-informed decisions about using digital endpoints. It also helps articulate the measurable
More news about: Digital Medicine Society (DiMe)
Mar 26, 2025, 02:49 ET GenScript Biotech Earns EcoVadis Bronze Medal for the Second Consecutive Year, Ranking Above 83% of Companies
GenScript, we believe that sustainability is not just a goal, but a fundamental part of our mission to make people and nature healthier through biotechnology. By optimizing operations and collaborating with our value chain, we have taken steps forward in reducing environmental impact, promoting ethical
More news about: GenScript Biotech Corporation
Mar 26, 2025, 02:06 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 17, 2024, inclusive
More news about: THE ROSEN LAW FIRM, P. A.
Mar 25, 2025, 19:30 ET Adcentrx Therapeutics to Showcase Novel STEAP1 and NaPi2b ADCs with Oral and Poster Presentations at AACR 2025
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present new data at the
More news about: Adcentrx Therapeutics
Mar 25, 2025, 16:35 ET Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Mar 25, 2025, 16:30 ET Rgenta Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Mass., March 25, 2025 /PRNewswire/ -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders,
More news about: Rgenta Therapeutics
Mar 25, 2025, 16:30 ET Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025
March 25, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and autoimmune diseases, will present updated clinical and translational
More news about: Marengo Therapeutics
Mar 25, 2025, 16:30 ET Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may
More news about: Elevation Oncology
Mar 25, 2025, 15:37 ET Skincare Supplement Market to Reach USD 5,857.59 million by 2032, growing at a 8.50% CAGR - Credence Research
Acquisitions January 2023 – Healthgevity, a dietary supplement company, partnered with Nuritas, a biotechnology firm, to launch LONGEVITY, an anti-aging precision peptide supplement powered by PeptiStrong, a patented next-generation ingredient derived from
More news about: Credence Research Inc.
Mar 25, 2025, 10:59 ET CS Analytical Extends High Voltage Leak Testing Capabilities with Addition of Nikka Densok HDL-1 HVLD Test System
world's only cGMP, FDA-registered and inspected contract laboratory exclusively designed and dedicated to container testing for the pharmaceutical, biotechnology, and medical device industries, is excited to announce that it has acquired, installed and qualified a Nikka Densok HDL-1 High Voltage Leak Detection
More news about: CS Analytical
Mar 25, 2025, 10:36 ET Hubble Therapeutics closes Series A Financing to develop gene therapy cure for LCA16
March 25, 2025 /PRNewswire/ -- Hubble Therapeutics LLC a patient-focused biotechnology company developing a gene therapy to cure pediatric blindness, announces the successful closing of a $7.3 million
More news about: Hubble Therapeutics LLC
Mar 25, 2025, 10:36 ET Hubble Therapeutics closes Series A Financing to develop gene therapy cure for LCA16
March 25, 2025 /PRNewswire/ -- Hubble Therapeutics LLC a patient-focused biotechnology company developing a gene therapy to cure pediatric blindness, announces the successful closing of a $7.3 million
More news about: Hubble Therapeutics LLC
Mar 25, 2025, 10:30 ET Drug Discovery Services Market worth US$27.23 billion in 2030 with 10.7% CAGR | MarketsandMarkets™
chemistry and structure-based drug design. In the therapeutic area, the oncology segment commanded the highest market share. Pharmaceutical and biotechnology companies are the largest end users, owing to high research & development investments. Download PDF Brochure:
More news about: MarketsandMarkets
Mar 25, 2025, 10:15 ET Caprolactam Market to Reach USD 25.77 Billion by 2031, Driven by Growing Demand in Nylon Production and Expanding Applications Across Industries: Market Research Intellect
alternatives. Traditional caprolactam production involves petrochemical feedstocks, which contribute to carbon emissions. However, advancements in biotechnology and green chemistry are enabling the production of bio-based caprolactam, reducing reliance on fossil fuels. Companies are investing in research
More news about: Market Research Intellect
Mar 25, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
March 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States
More news about: Pomerantz LLP
Mar 25, 2025, 09:31 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:
More news about: The Schall Law Firm
Mar 25, 2025, 09:15 ET WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY
March 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a biotechnology company focused on industrial manufacturing of ingredients is pleased to announce its financial and operating results for the three months and year
More news about: Willow Biosciences Inc.
Mar 25, 2025, 09:00 ET Truist Securities strengthens its biotech equity research coverage
that Danielle Brill has joined the firm as managing director, strengthening its equity research coverage in the biotechnology sector. Brill is the latest addition to Truist Securities, as the firm continues to expand its equity platform to broaden its capabilities in high-growth
More news about: Truist Financial Corporation